

Press briefing 2

Sunday, 28 September 2014, 8:15-9:00 (CEST)

Moderator: Eric Van Cutsem, University of Leuven, Leuven, Belgium

Programme

The data presented will refer to the following studies:

LBA2 Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the Phase III, randomised IMPRESS study	Tony Mok, The Chinese University of Hong Kong, Shatin, China
350O Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)	Sandra Swain, Washington Cancer Institute, Washington, United States
1173O MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)	Johan F. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
LBA25 CIRCCa: A randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. (CRUK Grant Ref: C1256/A11416)	Raymond Symonds, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, United Kingdom

Data presented at this Press Conference is embargoed until Sunday, 28 September 2014 at 9:00 CEST



Press conference

Sunday, 28 September 2014, 12:00-12:45 (CEST)

The methodology of clinical trials in rare tumours

Moderator: Jean-Yves Blay, Centre Leon Berard, Université Claude Bernard, Lyon, France

Speakers: Paolo G. Casali, Istituto Nazionale Tumori, Milan, Italy; Kathy Oliver, International Brain Tumour Alliance, London, United Kingdom, *others to be confirmed*

Programme (TBC)

During this press conference, journalists will be presented with the Rare Cancers Europe methodological recommendations for clinical studies in rare cancers, a multi-stakeholder position paper calling for different criteria to be used in clinical trials for rare cancer treatments.

Details to follow.